MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

407

Employees407

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

407

Employees407

MNKD Key Statistics

Market cap

1.57B

Market cap1.57B

Price-Earnings ratio

44.65

Price-Earnings ratio44.65

Dividend yield

—

Dividend yield—

Average volume

4.71M

Average volume4.71M

High today

$5.15

High today$5.15

Low today

$4.88

Low today$4.88

Open price

$4.92

Open price$4.92

Volume

4.52M

Volume4.52M

52 Week high

$7.63

52 Week high$7.63

52 Week low

$3.38

52 Week low$3.38

MNKD News

TipRanks 7h

MannKind’s Afrezza: Promising Expansion and Growth Potential with FDA sBLA Acceptance

Wedbush analyst Yun Zhong maintained a Buy rating on MannKind today and set a price target of $11.00. Elevate Your Investing Strategy: Take advantage of TipRank...

TipRanks 10h

MannKind announces U.S. FDA accepted sBLA for Afrezza Inhalation Powder

MannKind (MNKD) announced that the U.S. Food and Drug Administration, FDA, has accepted the supplemental biologics license application, sBLA, seeking approval f...

Simply Wall St 1d

MannKind: Evaluating Valuation Gaps and Growth Narratives in the Biotech Sector

MannKind (MNKD) stock has seen mixed performance lately, with shares down over the past month but recovering during the past 3 months. Investors continue to ass...

Analyst ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

More MNKD News

TipRanks 4d

MannKind Completes Acquisition of scPharma

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.